LINC01303 functions as a competing endogenous RNA to regulate EZH2 expression by sponging miR-101-3p in gastric...

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Long non-coding RNAs (lncRNAs) are key regulators in various malignancies.
• The roles of many lncRNAs in gastric cancer (GC) remain largely uncharacterized.
• LINC01303 is identified as significantly upregulated in GC tissues via TCGA data analysis.

Purpose of the Study:

• To investigate the biological function and clinical significance of LINC01303 in gastric cancer.
• To elucidate the underlying molecular mechanism of LINC01303 in GC progression.

Main Methods:

• Real-time quantitative PCR to measure LINC01303 expression in GC tissues.
• In vitro cell assays to assess the impact of LINC01303 knockdown on GC cell proliferation, migration, and invasion.
• In vivo studies to evaluate LINC01303's role in GC tumor growth.
• Bioinformatics analysis to identify potential molecular interactions of LINC01303.

Main Results:

• LINC01303 expression is significantly higher in GC tissues compared to adjacent tissues.
• Silencing LINC01303 effectively inhibits GC cell proliferation, migration, and invasion.
• LINC01303 knockdown suppresses GC tumor growth in vivo.
• Bioinformatics analysis reveals LINC01303 acts as a molecular sponge for miR-101-3p, competing with EZH2.

Conclusions:

• LINC01303 promotes gastric cancer progression by upregulating EZH2 expression through inhibition of miR-101-3p activity.
• The LINC01303/miR-101-3p/EZH2 axis is a novel mechanism driving GC progression.
• LINC01303 represents a potential therapeutic target for gastric cancer.